StockNews.com assumed coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research note published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Performance
NASDAQ XXII opened at $0.12 on Friday. The business’s 50 day moving average price is $0.29 and its 200-day moving average price is $0.81. 22nd Century Group has a fifty-two week low of $0.09 and a fifty-two week high of $8.81. The company has a market cap of $962,701.20, a P/E ratio of 0.00 and a beta of 1.39.
22nd Century Group (NASDAQ:XXII – Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The firm had revenue of $7.95 million during the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%.
Institutional Inflows and Outflows
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Articles
- Five stocks we like better than 22nd Century Group
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Trading Halts Explained
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What Are Some of the Best Large-Cap Stocks to Buy?
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.